For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
